IL-15 Is Overexpressed in γδ T Cells and Correlates with Disease Severity in Relapsing-Remitting Multiple Sclerosis.
IL-15
MS
multiple sclerosis
γδ T cells
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
15 Sep 2021
15 Sep 2021
Historique:
received:
12
08
2021
revised:
13
09
2021
accepted:
13
09
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
29
9
2021
Statut:
epublish
Résumé
Interleukin 15 (IL-15) is known to be involved in the pathogenesis of multiple sclerosis (MS). An animal study revealed a distinct subset of IL-15-producing γδ T cells that correlate with disease severity. The aim of the current study was to test whether such a subset is also present in humans and its importance for the pathogenesis of MS. The peripheral blood from 29 patients with relapsing-remitting MS (including 6 relapses) and 22 controls was stained with monoclonal antibodies and analyzed with flow cytometry. The existence of IL-15+ γδ T cells was confirmed. Moreover, the percentage of IL-15+ γδ T is significantly increased in MS patients and correlates with disease severity. Nevertheless, additional functional studies are needed to fully understand the importance of those cells in multiple sclerosis pathogenesis.
Identifiants
pubmed: 34575283
pii: jcm10184174
doi: 10.3390/jcm10184174
pmc: PMC8467081
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Uniwersytet Medyczny w Lublinie
ID : WFS21/2017
Références
Clin Immunol. 2004 Oct;113(1):56-63
pubmed: 15380530
Neurol Res. 2010 Sep;32(7):684-9
pubmed: 19703339
Singapore Med J. 2003 Dec;44(12):614-9
pubmed: 14770254
J Neuroimmunol. 2019 May 15;330:67-73
pubmed: 30831520
Neurology. 2014 Sep 9;83(11):1022-4
pubmed: 25200713
Scand J Immunol. 1999 Sep;50(3):302-8
pubmed: 10447940
J Neuroimmunol. 2010 Jun;223(1-2):65-72
pubmed: 20430449
Cytometry B Clin Cytom. 2008 Jan;74(1):40-4
pubmed: 17703441
Immunology. 2012 Jul;136(3):283-90
pubmed: 22385416
Eur J Immunol. 2014 Nov;44(11):3330-41
pubmed: 25142300
Cells. 2020 Feb 18;9(2):
pubmed: 32085540
J Neuroimmunol. 2002 Jul;128(1-2):90-4
pubmed: 12098515
Front Immunol. 2020 Sep 24;11:549842
pubmed: 33072089
J Immunol. 2011 Oct 15;187(8):4119-28
pubmed: 21911607
Cytokine. 2020 Dec;136:155258
pubmed: 32919253
Clin Exp Immunol. 1998 Jan;111(1):193-7
pubmed: 9472681
Front Immunol. 2020 Aug 28;11:1868
pubmed: 32983105
Mult Scler Relat Disord. 2021 Apr;49:102784
pubmed: 33508574
F1000Res. 2017 Jun 5;6:
pubmed: 28649364
Mult Scler. 2010 Jan;16(1):121-6
pubmed: 20007430
Arch Immunol Ther Exp (Warsz). 2021 Mar 4;69(1):4
pubmed: 33661375
Mol Immunol. 2015 Aug;66(2):402-8
pubmed: 25974878
Neurol Neuroimmunol Neuroinflamm. 2020 Dec 15;8(1):
pubmed: 33323466
J Immunol. 2010 Nov 15;185(10):5693-703
pubmed: 20926794
Anticancer Res. 2011 Dec;31(12):4099-109
pubmed: 22199267
Exp Neurol. 2010 Apr;222(2):235-42
pubmed: 20070942
J Neuroimmunol. 2019 Dec 15;337:577046
pubmed: 31505409
Int J Mol Sci. 2020 Nov 24;21(23):
pubmed: 33255339
Am J Manag Care. 2016 Jun;22(6 Suppl):s141-50
pubmed: 27356023
Cell Mol Immunol. 2013 Jan;10(1):50-7
pubmed: 23064104